Blood cancers

Triple combination highly active in mantle cell lymphoma: study

The combination of ibrutinib, obinutuzumab, and venetoclax was well tolerated and offered a promising response rate in a phase I/II trial of relapsed and untreated mantle cell lymphoma (MCL) patients. The Bruton tyrosine kinase inhibitor (BTKi) ibrutinib is already used to treat relapsed or refractory MCL in Australia and elsewhere. Resistance often develops, however, as ...

Already a member?

Login to keep reading.

© 2021 the limbic